Practical Dermatology

10/16/2025

📢 🗞️ OCTOBER ISSUE NOW ONLINE: This month’s issue of Practical Dermatology is now live on https://ow.ly/Rqe050XbZEY! The October cover focus dives into regenerative medicine and aesthetics, from surveying global trends to exploring legal issues surrounding growth factor treatments, offering a one-stop shop of diverse perspectives on how regenerative medicine is reshaping aesthetic care.

🧬 The October issue contains expert insights on topics such as:
• Injectables with regenerative benefits
• PDGF+ laser treatments in skin of color
• Building lifelong patient loyalty
• Upadacitinib and cardiovascular risk
• Much more!

📰 Get the full issue here ➡️ https://practicaldermatology.com/issues/october-2025/

10/15/2025

⛔ 📢 DISPARITIES AND BARRIERS DESPITE PROGRESS: A new DC Cohort study led by GWU researchers reveals that nearly half of people with HIV continue to face dermatologic disease, despite significant progress in antiretroviral therapy. Incidence has declined, but structural and immune-related disparities remain.

Read more ➡️ https://ow.ly/88O650XbTKn

10/13/2025

📚👨‍⚕️👨‍⚕️🎙️ NEW ATOPIC DERMATITIS JOURNAL CLUB: Drs. Neal Bhatia and Ted Lain dive into the potential combination of dupilumab + upadacitinib for treating severe atopic dermatitis, sharing insights from a recent International Journal of Dermatology article as well as their own clinical experience.

📺 Watch here ➡️ https://ow.ly/tcoS50X9WLt

10/11/2025

📢 📺 DERMWIRE TV EXTRA: ROCATINLIMAB TRIALS

Practical Dermatology sat down with cinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The ROCKET-Ignite Trial looked at the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe atopic dermatitis (AD), and the ROCKET-SHUTTLE trial suggested that rocatinlimab with concomitant topical therapy significantly improved clinical signs and symptoms of AD.

Watch here ➡️ https://ow.ly/FeIE50Xa2F9

10/10/2025

📺 🔬NEW DERMWIRE TV: This episode includes news on two major FDA approvals that have expanded effective treatment options for pediatric patients living with two different conditions:
✅ Roflumilast for pediatric atopic dermatitis
✅ Guselkumab for pediatric psoriatic disease

✨PLUS: mentorship moment from Dr. Tina Bhutani via YoungMD Connect, discussing academic vs. industry career paths in dermatology.

🎥 Watch the full episode: https://ow.ly/jmca50X9X7f

10/10/2025

🔬✨NEW: Results from a recent randomized trial showing that transcutaneous auricular vagus nerve stimulation (taVNS) improves facial erythema and also anxiety and depression in ETR patients.

Read more ➡️ https://ow.ly/6qbX50X9gT3

10/09/2025

🎙️👨‍⚕️👩‍⚕️👨‍⚕️ NEW PRACTICAL DERMATOLOGY PODCAST: Jason E. Hawkes, MD, MS, FAAD, discusses a recent consensus paper defining on-treatment remission for plaque psoriasis, and Theodore Rosen, MD, FAAD, joins associate medical editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss the threat posed by antimicrobial resistance and play “Two Truths and a Lie.”

🎧 Listen here ➡️ https://ow.ly/rYCF50X97SG

Jason E. Hawkes, MD, MS, FAAD, discusses a recent consensus paper defining on-treatment remission for plaque psoriasis, and Theodore Rosen, MD,...

10/08/2025

📢 GRANT OPPORTUNITY ALERT: Pfizer and GWU are re-launching their successful grant initiative to bring teledermatology care to underserved areas in the United States. The program aims to improve quality care through innovative virtual care models, focusing on common like AD and alopecia areata. Organizations based in the U.S. can apply for quality improvement funding through November 11. ✍️🗓️

Read more ➡️ https://ow.ly/t8lk50X8Aeq

10/07/2025

📢 📖 🔬 NEW AD JOURNAL CLUB: Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, is joined by Naiem T. Issa, MD, PhD, to discuss an article Dr. Issa authored reviewing published literature on the efficacy of biologics as monotherapy for atopic dermatitis (AD) following discontinuation. 📚 🔎

📺 Watch here ➡️

Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, is joined by Naiem T. Issa, MD, PhD, to discuss an article Dr. Issa authored...

10/06/2025

📢 🚨 BREAKING NEWS: The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% [Zoryve®, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)] for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor is the first steroid-free treatment in its class approved for this age group and is indicated for use on any area of the body, without duration limitations. 🧴👦🧒👶

Read more ➡️ https://ow.ly/7Czr50X71X0

The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of...

10/05/2025

🚫 🩺 BARRIERS TO DIAGNOSIS: A new study in JAMA Dermatology identified significant facilitators and barriers Latino patients face in receiving a timely melanoma diagnosis. Despite lower incidence rates, Latino populations often experience worse outcomes due to delayed care. 🔎📊

📖 Read more ➡️ https://ow.ly/30yP50X6LS9

10/03/2025

We’re live at the Skin of Color Update - Dermatology Conference in NYC! Great discussions so far on GLP-1s with Drs Jennifer Soung, MD and Karan Lal, and on energy-based devices with Drs Cheryl Burgess and Dr. Michelle Henry. Visit our website for coverage in the coming days!